.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
AstraZeneca
Argus Health
Baxter
Daiichi Sankyo
Cerilliant
Healthtrust
Chubb
Medtronic

Generated: December 12, 2017

DrugPatentWatch Database Preview

Tavaborole - Generic Drug Details

« Back to Dashboard

What are the generic sources for tavaborole and what is the scope of tavaborole patent protection?

Tavaborole
is the generic ingredient in one branded drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tavaborole has sixty-seven patent family members in twenty countries.

There are two drug master file entries for tavaborole. One supplier is listed for this compound.

Summary for tavaborole

Pharmacology for tavaborole

Ingredient-typeBoron Compounds
Drug ClassOxaborole Antifungal
Mechanism of ActionProtein Synthesis Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Anacor Pharms IncKERYDINtavaboroleSOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tavaborole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,353,133Boron-containing small molecules► Subscribe
7,767,657Boron-containing small molecules► Subscribe
8,889,656Boron-containing small molecules► Subscribe
8,440,642Boron-containing small molecules► Subscribe
8,722,917Boron-containing small molecules► Subscribe
8,115,026Boron-containing small molecules► Subscribe
8,039,451Boron-containing small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tavaborole

Country Document Number Estimated Expiration
Japan2016199561► Subscribe
Australia2010203096► Subscribe
China106008583► Subscribe
Japan2010248265► Subscribe
World Intellectual Property Organization (WIPO)2006089067► Subscribe
Japan6109140► Subscribe
Spain2414095► Subscribe
Japan2008535781► Subscribe
Japan2014132031► Subscribe
Australia2011200994► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
UBS
Fuji
Deloitte
Merck
McKesson
Harvard Business School
Moodys
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot